Mercury Laboratories Limited

Equities

MERCURYLAB6

INE947G01011

Pharmaceuticals

Delayed Bombay S.E. 05:21:56 2024-05-21 am EDT 5-day change 1st Jan Change
890 INR -2.83% Intraday chart for Mercury Laboratories Limited +5.20% -13.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Mercury Laboratories Names COO MT
Mercury Laboratories Limited Announces Promotion of Saurabh Mittal as Chief Operating Officer CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31,2023 CI
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Mercury Laboratories Limited Recommends Dividend for the Year 2022-23 CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Mercury Laboratories Limited Approves Creation of New Facility for Manufacturing Small Volume Parenteral(SVPs) At Jarod CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2022 CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Mercury Laboratories Limited Recommends Dividend for the Year 2022 CI
Mercury Laboratories Limited Announces Resignation of Kinjal Khandelwal as Company Secretary and Compliance Officer CI
Mercury Laboratories Limited Approves Appointment of Mr. Ashish Vasavada, as Chief Financial Officer CI
Mercury Laboratories Approves Interim Dividend and Final Dividend for the Year Ended March 31, 2021 CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Mercury Laboratories : Crisil Affirms FB+ Rating on Mercury Laboratories' Fixed Deposits; Outlook Stable MT
Mercury Laboratories' : CFO Tenders Resignation MT
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Mercury Laboratories Limited Recommends Dividend for Year Ended March 31, 2021 CI
Mercury Laboratories Limited Announces Resignation of Enu Khandelwal as CFO with Effect from June 22, 2021 CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Mercury Laboratories Limited Declares an Interim Dividend for the Financial Year 2020-21 CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020 CI
Chart Mercury Laboratories Limited
More charts
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. The Company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, among others. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW